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908Allogeneic Hematopoietic Cell Transplantation for
Chronic Myelomonocytic Leukemia: Relapse-Free
Survival Is Determined by Karyotype and
Comorbidities
Hesham Eissa,1,2,3 Ted A. Gooley,1,4 Mohamed L. Sorror,1 Franchesca Nguyen,1
Bart L. Scott,1,5 Kristine Doney,1,5 Keith R. Loeb,1,6 Paul J. Martin,1,5
John M. Pagel,1,5 Jerry P. Radich,1,5 Brenda M. Sandmaier,1,5
E. Houston Warren,1,5 Rainer Storb,1,5 Frederick R. Appelbaum,1,5 H. Joachim Deeg1,5Hematopoietic cell transplantation (HCT) offers potentially curative therapy for chronic myelomonocytic
leukemia (CMML). We evaluated HCToutcomes in 85 patients with CMML, 1.0-69.1 (median 51.7) years
of age, with follow-up extending to 19 years. CMML was considered de novo in 71 and secondary in 14
patients. Conditioning regimens were of various intensities. Thirty-eight patients had related (34 HLA
identical), and 47 (39 HLA matched) unrelated donors. The source of stem cells was marrow in 32 and
peripheral blood progenitor cells in 53 patients. Acute graft-versus-host disease (aGVHD) grades II-IV
occurred in 72% and chronic GVHD (cGVHD) in 26% of patients. Relapse incidence was 27% at 10 years.
Relapse correlated with increasing scores by the MDAnderson prognostic score (P5.01). The major causes
of death were relapse and infections6GVHD. Progression-free survival (PFS) was 38% at 10 years. Mortality
was negatively correlated with pre-HCT hematocrit (P 5 .007), and increased with high-risk cytogenetics
(P 5 .02), higher HCT Comorbidity Index (P 5 .0008), and increased age (P 5 .02). WHO classification
did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting
remissions following allogeneic HCT and appear to be cured of their disease.
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Chronic myelomonocytic leukemia (CMML), cur-
rently characterized as a myelodysplastic/myeloprolif-
erative disorder by World Health Organization
(WHO) criteria, is a heterogeneous disease with vari-
able course, generally ending in progression to acute
myeloid leukemia (AML). Various classification sys-
tems have been described [1]. The WHO distinguishes1Clinical Research Division, Fred Hutchinson Cancer Re-
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6/j.bbmt.2010.09.018CMML-1 (\10% marrow blasts) and CMML-2
(10%-20% blasts), for which median survival of 20
and 15 months, respectively, have been reported [2].
The International Prognostic Scoring System (IPSS),
recognized dysplastic and proliferative forms of
CMML [3], with JAK2 mutations present in approxi-
mately 10% of patients with proliferative CMML
[4-6]. Investigators at M.D. Anderson Cancer Center
proposed a 4-stage classification on the basis
of circulating immature cells, hemoglobin levels,
lymphocyte counts, and marrow blasts [1]. On the basis
of the presence of these risk factors, they divided pa-
tients into 4 groups with median life expectancies rang-
ing from 5 to 24months. Additional studies suggest that
younger age at the time of diagnosis, splenomegaly,
lymphadenopathy, elevated lactate dehydrogenase
(LDH) levels, and clonal cytogenetic abnormalities
are associated with a more rapid progression [7,8].
Although occasional patients have prolonged
remissions with aggressive chemotherapy, the only
current therapy with proven curative potential is
hematopoietic cell transplantation (HCT) [9-12].
Biol Blood Marrow Transplant 17:908-915, 2011 909Hematopoietic Cell Transplantation for CMMLWe reported previously results in 43 patients trans-
planted at the Fred Hutchinson Cancer Research
Center (FHCRC) [11]. Here, we present results in 42
new patients and provide long-term follow-up extend-
ing to 19 years for previously reported patients.PATIENTS AND METHODS
Patients and Disease Characteristics
Between May 1986 and December 2008, 85 pa-
tients with CMML had HCT at the FHCRC, 42 of
these since our initial report in 2005 [11]. All provided
informed consent for enrollment in investigational
protocols and for long-term follow-up as required by
the institutional review board of the FHCRC. Patient
and disease characteristics are summarized in Table 1.
Patients were 1.0 to 69.1 (median 51.7) years old. By
WHO criteria [13], 57 patients (67%) had CMML-1
and 26 (31%) had CMML-2; in 2 patients, the stagingTable 1. Patient and Disease Characteristics
Variable
Number of
Patients
Number of patients 85
Age (years), range (median) 1–69.1 (51.7)
Sex (male/female) 52/33
Diagnosis
FAB
Proliferative 28
Nonproliferative 54
WHO
CMML 1 57
CMML 2 26
IPSS risk
Low 8
Intermediate-1 23
Intermediate-2 15
High 7
MDAPS
Low 32
Intermediate-1 23
Intermediate-2 17
High 8
Hematology parameters median (range)
WBC (109/L) 7.38 (0.08-85.5)
Lymphocytes (109/L) 1.55 (0-12.83)
Platelets (109/L) 63 (7-882)
Hemoglobin (g/dL) 10.5 (7.2-15.7)
Cytogenetics risk (by IPSS)
Good 45
Intermediate 14
Poor 22
Pretransplantation therapy
None or transfusion only 13
Cytoreductive with or without HU 49
Differentiating agents 10
Splenectomy with or without other
treatment modalities
15
Other modalities 9
HU indicates hydroxyurea; FAB, French-American-British classification;
WHO, World Health Organization; IPSS, International Prognostic
Scoring System; MDAPS, MD Anderson Prognostic Score; WBC,
white blood cell count (see text); CMML, chronic myelomonocytic
leukemia.was inconclusive. In 54 patients (64%), the WBC was
\13,000 at HCT, thus qualifying as dysplastic
CMML. Among these 54 patients, 8 had low-risk, 23
intermediate-1, 15 intermediate-2, and 7 high-risk dis-
ease by IPSS criteria [3] (cytogenetic information was
missing for 1 patient). Among 81 patients with cytoge-
netic data, 45 (53%) were considered good risk, 14
(16%) intermediate risk, and 22 (26%) poor risk ac-
cording to IPSS criteria. Using the M.D. Anderson
prognostic score (MDAPS), 32 patients had low-risk,
23 intermediate-1, 17 intermediate-2, and 8 high-risk
disease (data incomplete in 5 patients).
In 14 patients, CMMLwas thought to be ‘‘second-
ary,’’ following treatment for non-Hodgkin or Hodg-
kin lymphoma in 4, aplastic anemia in 2, breast
cancer in 2, and 1 each for idiopathic thrombocytope-
nic purpura, chronic lymphocytic leukemia, Wege-
ner’s granulomatosis, rhabdomyosarcoma, AML, and
liver transplantation.
Treatment before transplantation included trans-
fusions alone in 13 patients; 49 patients received hy-
droxyurea or cytoreductive chemotherapy or both;
10 received erythropoietin, prednisone, or differenti-
ating agents alone or in combination. Fifteen under-
went splenectomy with or without other therapeutic
modalities. Nine received other treatment including
azacytidine or decitabine in 5, imatinib in 2, thalido-
mide and lenalidomide in 2.
TheHCT comorbidity index (HCT-CI) score was
0 in 19, 1-2 in 23, 3 in 19, and 4-11 in 18 patients; the
score could not be calculated in 8 patients because of
missing data [14].Donor and Transplant Characteristics
Donor and transplant characteristics are summa-
rized in Table 2.Donor Selection
HLA typing of related donors involved
intermediate-resolution molecular typing for HLA-A,
-B, -C, and -DQB1, and high-resolution typing for
DRB1 [15]. Unrelated donors were typed for HLA-A,
-B, -C, and -DRB1 by high-resolution and for DQB1
by intermediate-resolution typing [15]. Thirty-eight
patients (45%) had related donors; 32 were genotypi-
cally HLA-identical siblings, 2 were HLA-matched
family members other than siblings, 4 were HLA
nonidentical family members (parent differing for
HLA-A; sibling differing for HLA-A, -B, and -DR;
child differing for HLA-A and -DR; in 1 the donor in-
formation was incomplete), and 47 (55%) had unrelated
donors, 39 were HLA matched, and 8 were HLA
nonidentical (4 differing for HLA-A, 3 for HLA-DR,
and 1 with an undetermined mismatch).
Table 2. Donor and Transplant Characteristics
Variable
Number
of
Patients
Donor age (years), range (median) 3.4-69.1 (40.1)
Sex, male/female 51/34
Donor/patient CMV status*
2/2 21
2/+ 26
+/+ 25
+/2 11
Donor patient relationship
–Related
HLA-identical sibling 32
HLA-matched relative other than
sibling
2
HLA-mismatched relative 4
–Unrelated
HLA-matched 39
HLA-mismatched 8
Donor/patient sex
F/F 13
F/M 21
M/F 20
M/M 31
Conditioning regimen†
BU (7 mg/kg)/CY (50 mg/kg)/TBI
(12 Gy)
10
BU (7 mg/kg)/TBI (12 Gy) 11
BU (16 mg/kg)/CY (120 mg/kg)/THY
(4.5 mg/kg)
29
CY (120 mg/kg)/TBI (14.4 or 13.2 Gy) 8
TBI (2-3 Gy) ± FLU (90 mg/m2) 6
FLU (120 mg/m2)/BU (16 mg/kg) 12
TBI (2 Gy)/iodine 131-anti-CD45
antibody
6
FLU (150 mg/m2)/Treosulfan
(314 g/m2)
3
GVHD prophylaxis regimen
CSP/MTX 44
CSP/MMF 12
CSP/other combinations 6
FK506/MTX 20
FK506/MMF 3
Source of stem cells
Marrow 32
PBPC 53
Cell dose, range (median)
Marrow 0.7-7.8 (2.9)  108/kg
PBPC (CD34+) 4.0-30.0 (10.9)  106/kg
Bu indicates busulfan; CMV, cytomegalovirus; CSP, cyclosporine; HLA,
human leukocyte antigen; F, female; FK506, tacrolimus; Flu, fludarabine;
M, male; MMF, mycophenolate mofetil; MTX, methotrexate; PBPC, pe-
ripheral blood progenitor cells; TBI, total-body irradiation; GVHD, graft-
versus-host disease.
*Data missing for 2 donors.
†Eight patients (4 conditioned with targeted BU/CY, 4 conditioned with
FLU/targeted BU, and 1 conditioned with CY/TBI) also received antith-
ymocyte globuline (ATG). One patient conditioned with BU/CY was
also given amifostine, 340 mg/m2 [29].
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The stem cell source was bone marrow in 32
(38%), and granulocyte-colony stimulating factor
(G-CSF)-mobilized peripheral blood progenitor cells
(PBPC) in 53 patients (62%).
Conditioning Regimen
Conditioning regimens were determined by
sequential protocols active at the time of HCT(Table 2). Ten patients were conditioned with busul-
fan (BU) 7 mg/kg orally (p.o.), cyclophosphamide
(CY) 50 mg/kg intravenously (i.v.), and total-body
irradiation (TBI) 6  200 cGy over 3 days for a total
of 12 Gy. Eleven patients received BU, 7 mg/kg p.o.
and TBI, 6  200 cGy over 3 days for a total of 12
Gy. Twelve patients received fludarabine 120 mg/m2
i.v. over 3 days and BU 16 mg/kg p.o. over 4 days (tar-
geted to plasma levels of 800-900 ng/mL). Twenty-
nine patients received BU 16 mg/kg p.o. (targeted to
plasma levels of 800-900 ng/mL) plus CY 120 mg/kg
i.v.; 8 patients received CY 120mg/kg i.v. and fraction-
ated TBI 14.4/13.2 Gy over 3 to 4 days; 6 patients
received 131I conjugated anti-CD45 antibody i.v.
combined with TBI, 200 cGy and fludarabine 3  30
mg/m2 i.v.; 6 received TBI 2 or 3 Gy, with or without
the addition of fludarabine, 3  30 mg/m2 i.v.; and 3
patients received fludarabine 5  30 mg/m2 i.v. plus
treosulfan 14 g/m2 i.v. [16].
Graft-versus-Host Disease (GVHD) Prophylaxis
GVHD prophylaxis consisted of cyclosporine
(CSP) and methotrexate (MTX) in 44 patients, tacro-
limus and MTX in 20, CSP and mycophenolate mofe-
til (MMF) in 12, tacrolimus and MMF in 3, and CSP
plus other combinations [17] in 6 patients.
Evaluation
Engraftment was defined as the first of 3 consecu-
tive days with an absolute neutrophil count (ANC)
$0.5  109/L, and platelet engraftment as the first of
3 days with platelet counts of .20  109/L, without
transfusion support. Acute GVHD (aGVHD) and
chronic GVHD (cGVHD) severity were assessed and
treated as described previously [18-20]. We did not
reclassify cGVHD according to the more recently
developed National Institutes of Health (NIH)
consensus criteria [21,22].
Relapse/disease progression was defined as reap-
pearance/persistence of host cells with the morpho-
logic, cytogenetic, molecular, or immunophenotypic
markers of the disease pretransplant.
Statistical Analysis
Survival was defined as the time from transplant to
death or date of last contact. Relapse-free survival
(RFS) was defined as the time from transplant to re-
lapse or death by causes other than relapse. Nonrelapse
mortality (NRM) was defined as death without prior
relapse. Estimates of the probability of overall survival
(OS) and RFS were obtained by the Kaplan-Meier
method, and estimates of the probability of relapse,
NRM, and cGVHD were summarized using cumula-
tive incidence estimates. Death without relapse was
considered a competing risk for NRM, NRM a com-
peting risk for relapse, and death without cGVHD
Table 3. Univariate Regression Results
Factor Overall Mortality Mortality or Relapse NRM Relapse
MD Anderson 1.11 (0.87-1.42, P 5 .40) 1.14 (0.90-1.45, P 5 .29) 0.88 (0.63-1.21, P 5 .42) 1.63 (1.11-2.39, P 5 .01)
Prognostic Score*
WBC >13  109/L 1 1 1 1
WBC <13  109/L 1.11 (0.60-2.05, P 5 .74) 0.99 (0.55-1.78, P 5 .96) 0.88 (0.40-1.93, P 5 .75) 1.14 (0.46-2.79, P 5 .78)
Patient/donor sex
M/M 1 1 1 1
F/F 0.90 (0.41-1.99, P 5 .79) 1.07 (0.50-2.31, P 5 .85) 0.41 (0.12-1.42, P 5 .16) 3.55 (1.04-12.13, P 5 .04)
F/M 0.58 (0.26-1.28, P 5 .18) 0.63 (0.29-1.36, P 5 .24) 0.33 (0.11-0.99, P 5 .05) 1.75 (0.49-6.21, P 5 .39)
M/F 0.81 (0.39-1.66, P 5 .56) 0.85 (0.41-1.74, P 5 .65) 0.62 (0.25-1.53, P 5 .30) 1.68 (0.45-6.25, P 5 .44)
Global P 5 .60 Global P 5 .61 Global P 5 .16 Global P 5 .22
Patient/donor CMV status
2/2 1 1 1 1
+/+ 1.37 (0.62-3.02, P 5 .43) 1.32 (0.60-2.90, P 5 .50) 1.38 (0.50-3.80, P 5 .53) 1.22 (0.34-4.32, P 5 .76)
+/2 1.45 (0.66-3.21, P 5 .35) 1.68 (0.78-3.65, P 5 .19) 1.55 (0.56-4.26, P 5 .40) 1.89 (0.57-6.27, P 5 .30)
2/+ 1.03 (0.37-2.84, P 5 .95) 1.07 (0.39-2.94, P 5 .90) 0.62 (0.13-3.07, P 5 .56) 1.69 (0.42-6.76, P 5 .46)
Global P 5 .75 Global P 5 .55 Global P 5 .61 Global P 5 .71
Hemoglobin* 0.86 (0.73-2.36, P 5 .37) 0.87 (0.75-1.02, P 5 .09) 0.87 (0.70-1.08, P 5 .21) 0.87 (0.69-1.10, P 5 .24)
Hematocrit* 0.92 (0.87-0.98, P 5 .007) 0.94 (0.89-0.99, P 5 .02) 0.92 (0.85-0.99, P 5 .03) 0.96 (0.89-1.04, P 5 .34)
Lymphocytes* 1.00 (0.90-1.12, P 5 .96) 1.02 (0.91-1.13, P 5 .77) 0.95 (0.80-1.13, P 5 .55) 1.08 (0.94-1.23, P 5 .29)
Platelets* 1.00 (0.99-1.00, P 5 .05) 1.00 (0.99-1.00, P 5 .07) 1.00 (0.99-1.00, P 5 .15) 1.00 (0.99-1.00, P 5 .27)
Donor
Matched sibling 1 1 1 1
Nonsibling relative 0.45 (0.10-1.96, P 5 .29) 0.44 (0.10-1.93, P 5 .28) 0.45 (0.06-3.63, P 5 .46) 0.43 (0.05-3.46, P 5 .43)
Unrelated 1.03 (0.56-1.91, P 5 .92) 1.11 (0.60-2.04, P 5 .74) 1.26 (0.55-2.91, P 5 .58) 0.95 (0.39-2.33, P 5 .91)
Cytogenetics
Good/intermediate 1 1 1 1
Poor 2.12 (1.15-3.90, P 5 .02) 2.20 (1.21-3.99, P 5 .009) 2.20 (1.00-4.82, P 5 .05) 2.20 (0.89-5.47, P 5 .09)
Source of stem cells
PBPC 1 1 1 1
Marrow 1.40 (0.80-2.47, P 5 .24) 1.31 (0.75-2.30, P 5 .34) 1.52 (0.73-3.15, P 5 .26) 1.08 (0.45-2.57, P 5 .87)
No excess blasts 1 1 1 1
Excess elasts 0.97 (0.55-1.71, P 5 .92) 1.00 (0.57-1.74, P 5 .99) 0.83 (0.40-1.73, P 5 .62) 1.29 (0.54-3.07, P 5 .57)
CMML2 1 1 1 1
CMML1 1.10 (0.59-2.02, P 5 .77) 1.07 (0.59-1.94, P 5 .83) 1.57 (0.67-3.67, P 5 .30) 0.68 (0.28-1.61, P 5 .38)
Cytogenetics (Spanish)* 2.07 (1.13-3,82, P 5 .02) 2.11 (1.17-3.83, P 5 .01) 2.83 (1.32-6.07, P 5 .008) 1.36 (0.50-3.71, P 5 .55)
IPSS* 1.28 (0.89-1.86, P 5 .19) 1.27 (0.88-1.82, P 5 .21) 1.22 (0.76-1.98, P 5 .41) 1.33 (0.76-2.32, P 5 .32)
HCT-CI 0-2 1 1 1 1
HCT-CI >2 2.80 (1.53-5.14, P 5 .0008) 2.53 (1.41-4.55, P 5 .002) 4.31 (1.79-10.39, P 5 .001) 1.47 (0.62-3.47, P 5 .38)
Age* 1.02 (1.00-1.04, P 5 .06) 1.02 (1.00-1.04, P 5 .06) 1.03 (0.99-1.06, P 5 .06) 1.01 (0.98-1.04, P 5 .47)
Disease duration* 1.02 (0.90-1.17, P 5 .75) 1.02 (0.90-1.17, P 5 .73) 0.88 (0.63-1.20, P 5 .43) 1.10 (0.96-1.24, P 5 .18)
Chronic GVHD† 1.15 (0.55-2.40, P 5 .70) 1.19 (0.56-2.54, P 5 .66) 2.33 (0.62-8.68, P 5 .21) 0.82 (0.31-2.13, P 5 .68)
Year of transplant* 0.99 (0.94-1.04, P 5 .69) 1.00 (0.95-1.05, P 5 .85) 0.99 (0.93-1.06, P 5 .81) 1.00 (0.93-1.08, P 5 .99)
For age, year of transplant, and disease duration, 1 unit corresponds to 1 year. For pretransplant hematologic parameters the units were as follows;
hemoglobin: g/L; hematocrit: percent; lymphocytes and platelets:109/L.
M indicates male; F, female; CMV, cytomegalovirus; PBPC, peripheral blood progenitor cells; IPSS, International Prognostic Scoring System; HCT-CI,
hematopoietic cell transplantation comorbidity index; GVHD, graft-versus-host disease; NMR, nonrelapse mortality.
*Modeled as continuous linear variables; HR (hazard ratio) reflects increase in hazard associated with increase in 1 unit.
†Modeled as time-dependent covariate.
Biol Blood Marrow Transplant 17:908-915, 2011 911Hematopoietic Cell Transplantation for CMMLa competing risk for cGVHD. Association of various
factors with the cause-specific hazard of failure for
each of these endpoints was assessed using Cox regres-
sion. The factors assessed, along with univariate re-
gression results, are contained in Table 3. All 2-sided
P values from regression models were estimated using
theWald test, and no adjustments were made for mul-
tiple comparisons. Data were analyzed as of 1/27/10.RESULTS
Engraftment
Seventy-seven patients (91%) achieved sustained
engraftment, as defined by neutrophil counts of 0.5 
105/L, at 9 to 31 (median 18) days, including 1 patient,
preparedwith a reduced intensity regimen, in whom theANC never declined below 0.5  105/L. Seven of the
remaining 8 patients died between day 11 and day 80
without achieving ANC 0.5  105/L. One patient
showed 100%donor cells (CD31 and CD331) initially,
but never achieved a neutrophil count of$0.5  109/L
and died on day 438 with recurrent CMML. A
transfusion-independent platelet count of 20  109/L
or greater was reached at 8 to 97 (median 14.5) days,
by 67 patients (79%); 18 patients died between days
11 and 115 without platelet reconstitution.GVHD
Acute GVHD of grades II–IV developed in 58
(72%), and grades III–IV in 21 (26%) of the 81 patients
who were assigned a grade. Chronic GVHD occurred
in 37 patients by 2 years for a cumulative incidence
Figure 1. Survival, relapse, and NRM. Shown for all patients are overall
and disease (relapse)-free survival (DFS, RFS), and the probabilities of
relapse and NRM. Tickmarks indicate censored patients.
912 Biol Blood Marrow Transplant 17:908-915, 2011H. Eissa et al.estimate of 44%. In addition, 1 patient was diagnosed
with cGVHDnearly 8 years following transplantation.
Relapse and NMR
Relapse or progression of CMML occurred in 22
patients between 28 and 1585 (median 183) days after
transplantation (Figure 1). The estimated probability
of relapse or disease progression was 24% at 2 years
and 27% at 10 years. Univariate regression models
are summarized in Table 3. MDAPS was statistically
significantly associated with the risk of relapse,
whereas poor-risk cytogenetics were suggestively asso-
ciated with the risk of relapse. Female patients with
a female donor had a higher risk of relapse compared
to male patients transplanted from a male donor, al-
though the univariate global P value for patient/donor
gender was P 5 .22. In a multivariable regression
model (Table 4), MDAPS showed a similar magnitude
of association as in the univariate model, whereas
patient/donor sex showed a suggestive association (in
particular, F/F compared to M/M).Table 4. Multivariable Analysis of Outcomes (Hazard Ratio [95% C
Relapse NRM
Patient/Donor Sex
M/M 1
F/F 4.64 (1.20-18.01, P 5 .03)
F/M 1.86 (0.45-7.69, P 5 .39)
M/F 1.60 (0.35-7.19, P 5 .54)
Global P 5 .10
MDAPS 1.65 (1.11-2.45, P 5 .01)
Hematocrit 0.92 (0.84-1.00, P 5
HCT-CI
0-2 1
>2 3.97 (1.54-10.23, P 5
Cytogenetics (IPSS)
Good/Interm. 1
Poor 3.09 (1.21-7.88, P 5
Age 1.04 (1.00-1.07, P 5
F indicates female; HCT-CI, hematopoietic cell transplantation comorbidity i
M, male; NRM, nonrelapse mortality; MDAPS, MD Anderson Prognostic ScorOverall, 29 deaths without a prior relapse had oc-
curred by the time of last contact, for a 2-year estimate
of NRM of 33%, and a 10-year estimate of NRM of
34%. As indicated in Table 3, in univariate regression
models, pretransplant hematocrit, cytogenetics, Span-
ish classification, HCT-CI, and age showed statisti-
cally significant or suggestive associations with the
risk of NRM. In a multivariable regression model,
each of these covariates showed a statistically signifi-
cant association with NRM, although cytogenetics
and Spanish classification failed to show an association
when both were included in the model, because of the
strong correlation between these 2 factors.Causes of Death
At the time of last contact (database locked on 01/
27/2010), 49 patients had died, 20 with progression or
relapse of CMML and 29 from nonrelapse causes.
These included multiorgan failure (n 5 13, associated
withGVHDin 2), viral or fungal infections (n5 7), cen-
tral nervous system or pulmonary hemorrhage (n 5 2),
respiratory failure (n 5 2), and GVHD (n 5 2); in
3 patients, the cause of death was not determined.OS and RFS
Currently 36 patients are surviving (34 in remis-
sion) at 0.5 to 19.1 (median 5.2) years, with a probabil-
ity of survival (RFS) at 10 years of 40% (38%)
(Figure 1).
Univariate regression models are summarized in
Table 3. For both OS and RFS, the same factors
were either statistically significantly or suggestively as-
sociated with outcome (pretransplant hemoglobin, he-
matocrit, and platelet counts; cytogenetics, HCT-CI,
age, and Spanish classification). In a multivariable re-
gression model, increasing pretransplant hematocrit
was associated with decreased mortality and increased
RFS, and increasing age, higher HCT-CI (Figure 2),onfidence Limits, P Value])
Mortality or Relapse Overall Mortality
.06) 0.94 (0.88-1.00, P 5 .04)
1 1
.004) 2.46 (1.33-4.54, P 5 .004) 2.62 (1.36-5.05, P 5 .004)
1 1
.02) 3.35 (1.73-6.48, P 5 .0003) 2.73 (1.37-5.44, P 5 .004)
.06) 1.03 (1.01-1.06, P 5 .009) 1.03 (1.00-1.05, P 5 .02)
ndex; HR, hazard ratio; IPSS, International Prognostic Scoring System;
e.
Figure 2. Survival dependent upon pretransplant comorbidities.
Shown are the probabilities of survival for 42 patients with HCT-CI
scores 0-2 (52.7%), and for 37 patients with scores of 3 or greater
(26.6%).
Biol Blood Marrow Transplant 17:908-915, 2011 913Hematopoietic Cell Transplantation for CMMLand poor-risk cytogenetics were each associated with
increased mortality and reduced RFS (Table 4).Figure 3. Survival by conditioning regimen. Shown are survivals with
specific conditioning regimens of various dose intensities. (The group of
3 patients conditioned with fludarabine and treosulfan is not included.)DISCUSSION
CMML is a hematopoietic malignancy with dys-
plastic and proliferative characteristics. Although
some patients have a relatively indolent disease course
extending over several years, others progress rapidly to
acute leukemia. Intensive chemotherapy as used for re-
mission induction in patients with acute leukemia has
met with limited success. The probability of achieving
complete remissions is low, and remission duration has
been short. A randomized trial comparing etoposide
and hydroxyurea showed superior survival with
hydroxyurea [23]. More recent trials using farnesyl
transferase inhibitors [24] or hypomethylating agents
[25] showed less early toxicity and mortality than ob-
served with conventional chemotherapy, but typically
resulted in only short-lasting responses.
HCT is currently the only treatmentmodality with
proven curative potential, offering the chance of long-
term survival. The present findings confirm our earlier
results, showing an estimated posttransplant survival
probability of 40% at 10 years with follow-up of sur-
viving patients extending to 2 decades. The major fac-
tors determining long-term RFS as well as OS were
pretransplant hematocrit, cytogenetic risk category,
comorbidity index, and age. Although disease classifi-
cation by MDAPS criteria could predict the risk of re-
current malignancy, as already suggested by our initial
report [11], neither this nor any other classification ex-
amined in the present analysis statistically significantly
affected long-term survival or RFS. However, the pa-
rameters identified as significant were reminiscent of
those described by Spanish investigators as determin-ing survival in nontransplanted patients [7]. In an anal-
ysis of data on 419 patients who had been followed for
amedian of 33months, these investigators identified in
univariate analysis CMML-2 with the presence of 2 or
3 peripheral blood cytopenias, poor-risk cytogenetics
(defined as trisomy-8 or complex karyotype), and red
blood cell transfusion dependence as factors that
were associated with shorter OS and higher risk of
evolution to acute leukemia (P\ .001) [7].
Of note, patient age, CMV status, source of stem
cells, and type of donor did not statistically significantly
affect OS or RFS, although female-to-female trans-
plants were associated with a higher probability of
relapse compared to male-to-male transplants in uni-
variate analysis. Whether patient/donor gender is truly
associated with relapse or is a product of multiple com-
parisons is not known. A global analysis of the 4 gender
combinations was not statistically significant (P5 .10),
and lacking a biologic explanation for this association,
we acknowledge that the observed association may
not be real. Similarly, the type of conditioning regimen
did not statistically significantly affect outcome; it ap-
peared, however, that patients conditioned with fludar-
abine and targeted busulfan had a low relapse incidence
and the highest probability of survival (Figure 3). Many
reports on transplant outcome in patients with myelo-
dysplastic syndromes (MDS) included patients with
CMML [9,12,26], whereas few focused on this disease
group exclusively [10,11,27]. A report from the Mayo
Clinic on 17 patients with CMML, 26 to 60 years of
age, showed a 41% NRM, with 3 patients (18%)
surviving in remission at a median follow-up of about
3 years. The incidence of relapse was 41%. A report
from King’s College in London summarized results in
18 patients, 38-66 years of age, most of whom
had received T cell–depleted transplants following flu-
darabine/busulfan conditioning [28]. The 3-year overall
survival was 31%, and the relapse incidence 47%. Sim-
ilar to the present study, high-risk cytogenetics were as-
sociated with mortality; however, small patient
914 Biol Blood Marrow Transplant 17:908-915, 2011H. Eissa et al.numbers prevented a strong statistical assessment. Mit-
tal et al. [26] included 7 patients withCMML in a report
from the M.D. Anderson Cancer Center, showing
a RFS of 37% with a median follow-up of 1.5 years.
Kroger et al. [27] reported RFS of 18% at 40 months,
in a study summarizing results from multiple institu-
tions, some of which used T cell depletion of the stem
cell inoculum. The present results in patients trans-
planted at a single institution compare favorably with
those data.
All published reports, including the present one,
have identified disease relapse as a major problem, oc-
curring in 25% to .40% of patients. It was of note,
however, that the cumulative incidence of relapse in
the small cohort of patients conditioned with a low-
intensity regimen of fludarabine and 200 cGy of
TBI, 25%, was not significantly different from the in-
cidence observed with higher intensity regimens, con-
sistent with a clinically relevant graft-versus-leukemia
effect as also suggested by other investigators [10,27].
Even so, survival with this regimen was not im-
proved relative to other conditioning strategies, con-
ceivably related to higher rates of comorbidities in
patients included in this cohort. Although patient
selection bias obviously could play a large role, the
similar incidence rates of relapse with conditioning
regimens of various intensities suggest that modalities
other than cytotoxic therapy should be incorporated
into transplant regimens for patients with CMML.
OS and RFS in this updated analysis were similar
to results presented in our previous report [11].
High-risk karyotypes were correlated with high re-
lapse rates, although the impact of karyotype de-
creased in multivariable analysis when other factors,
including hematologic parameters pretransplant were
entered into the analysis. The effect of these factors in-
dicates that the MDAPS or the Spanish classification
identifies parameters with significant impact on trans-
plant outcome [1]. As in our initial study [11], comor-
bidity scores were correlated with increasing NRM.
Thus, although currently used transplant regimens
may be quite effective in patients without significant
comorbidities and with good-risk cytogenetics, new
strategies are required for patients with high-risk
features. Whether the use of radioactive isotope–
conjugated antibodies to hematopoietic cells in the
conditioning regimen can improve overall results re-
mains to be determined. The subcohort of patients
in the present study that was treated by this approach
was too small to allow for firm conclusions.
Our observation that disease parameters identified
as prognostically relevant in patients not undergoing
HCT were also prognostically relevant for outcomes
after HCT is of note. For one, this observation should
allow to select high-risk patients for HCT. Second, it
might be possible to identify patients with deteriorat-
ing parameters and possibly proceed with HCT earlierthan would have otherwise have been the case. Clearly,
the HCT-CI, hematologic parameters, and cyto-
genetic findings are the factors with the most profound
impact on posttransplant outcome, and novel regimens
with low toxicity but greater efficacy in patients with
high-risk cytogenetics must be developed.ACKNOWLEDGMENTS
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